Fiscal Year (FY) 2009 Funding Opportunity, 39704 [E9-18873]
Download as PDF
<![CDATA[
39704
Federal Register / Vol. 74, No. 151 / Friday, August 7, 2009 / Notices
challenging economic times. In
addition, the National Suicide
Prevention Lifeline crisis centers are
community resources that need to be
utilized to reach out to those in their
communities most at risk, including
those currently impacted severely by the
economy.
Contact: Shelly Hara, Substance
Abuse and Mental Health Services
Administration, 1 Choke Cherry Road,
Room 8–1081, Rockville, MD 20857;
telephone: (240) 276–2321; E-mail:
shelly.hara@samhsa.hhs.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2009 Funding
Opportunity
pwalker on DSK8KYBLC1PROD with NOTICES
AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of intent to award a
Single Source Grant to Link2Health
Solutions, Inc.
SUMMARY: This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) intends to award
approximately $1,038,000 (total costs)
for up to one year to Link2Health
Solutions, Inc. This is not a formal
request for applications. Assistance will
be provided only to Link2Health
Solutions, Inc based on the receipt of a
satisfactory application that is approved
by an independent review group.
Funding Opportunity Title: SM–09–
020.
Catalog of Federal Domestic
Assistance (CFDA) Number: 93.243.
Authority: Section 520(A) of the
Public Health Service Act, as amended.
Justification: Only an application
from Link2Health Solutions will be
considered for funding under this
announcement. One-year funding has
become available to assist SAMHSA in
responding to the growing and pressing
need to provide resources for
individuals stressed by the nation’s
current economic crisis. It is considered
most cost-effective and efficient to
supplement the existing grantee for the
National Suicide Prevention Lifeline
and to build on the existing capacity
and infrastructure within its network of
crisis centers.
Link2Health Solutions is in the
unique position to carry out the
activities of this grant announcement
because it is the current recipient of
SAMHSA’s cooperative agreement to
manage the National Suicide Prevention
Lifeline. As such, Link2Health
Solutions has been maintaining the
network communications system and
has an existing relationship with the
networked crisis centers.
The crisis centers that comprise the
National Suicide Prevention Lifeline are
a critical part of the nation’s mental
health safety net. Many crisis centers are
experiencing significant increases in
calls. The National Suicide Prevention
Lifeline crisis centers require assistance
to continue to play their critical role in
providing support as well as emergency
services to suicidal callers during these
VerDate Nov<24>2008
17:09 Aug 06, 2009
Jkt 217001
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
[FR Doc. E9–18873 Filed 8–6–09; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0354]
Guidance for Industry on
Pharmaceutical Components at Risk
for Melamine Contamination;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘Pharmaceutical Components at
Risk for Melamine Contamination.’’
This guidance provides
recommendations that will help
pharmaceutical manufacturers of
finished products, repackers, other
suppliers, and pharmacists who engage
in drug compounding avoid the use of
components that are at risk for
melamine contamination. As of the date
of this announcement, FDA is not aware
of any pharmaceutical components that
are contaminated with melamine.
DATES: Submit written or electronic
comments on the guidance by October
6, 2009. General comments on agency
guidance documents are welcome at any
time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002; or the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on the
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Frank W. Perrella, Center for Drug
Evaluation and Research (HFD–
320), Food and Drug
Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 4337,
Silver Spring, MD 20993–0002,
301–796–3265; or
Brian Hasselbalch, Center for Drug
Evaluation and Research (HFD–
320), Food and Drug
Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 4364,
Silver Spring, MD 20993–0002,
301–796–3279; or
Diane Heinz, Center for Veterinary
Medicine (HFV–6), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–276–
9031.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance for industry entitled
‘‘Pharmaceutical Components at Risk for
Melamine Contamination.’’ This
guidance provides recommendations
that will help pharmaceutical
manufacturers of finished products,
repackers, other suppliers, and
pharmacists who engage in drug
compounding to better control their use
of at-risk components that might be
contaminated with melamine. The
guidance explains that the agency is
recommending that at-risk components
be properly tested for melamine
contamination before they are used in
the manufacture or preparation of drugs
or drug products. This recommendation
applies to nitrogen-based components.
As discussed in the guidance, FDA
has posted on its Web site methods for
measuring melamine contamination in
foods using liquid chromatography
triple quadrupole tandem mass
spectrometry (LC–MS/MS) and gas
chromatography/mass spectrometry
(GC–MS). Although these methods have
been evaluated using dry protein
materials, they can also be applicable to
other material, including at-risk
components. Manufacturers are
encouraged to validate test methods that
E:\FR\FM\07AUN1.SGM
07AUN1
]]>Agencies
[Federal Register Volume 74, Number 151 (Friday, August 7, 2009)]
[Notices]
[Page 39704]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-18873]
[[Page 39704]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Fiscal Year (FY) 2009 Funding Opportunity
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice of intent to award a Single Source Grant to Link2Health
Solutions, Inc.
-----------------------------------------------------------------------
SUMMARY: This notice is to inform the public that the Substance Abuse
and Mental Health Services Administration (SAMHSA) intends to award
approximately $1,038,000 (total costs) for up to one year to
Link2Health Solutions, Inc. This is not a formal request for
applications. Assistance will be provided only to Link2Health
Solutions, Inc based on the receipt of a satisfactory application that
is approved by an independent review group.
Funding Opportunity Title: SM-09-020.
Catalog of Federal Domestic Assistance (CFDA) Number: 93.243.
Authority: Section 520(A) of the Public Health Service Act, as
amended.
Justification: Only an application from Link2Health Solutions will
be considered for funding under this announcement. One-year funding has
become available to assist SAMHSA in responding to the growing and
pressing need to provide resources for individuals stressed by the
nation's current economic crisis. It is considered most cost-effective
and efficient to supplement the existing grantee for the National
Suicide Prevention Lifeline and to build on the existing capacity and
infrastructure within its network of crisis centers.
Link2Health Solutions is in the unique position to carry out the
activities of this grant announcement because it is the current
recipient of SAMHSA's cooperative agreement to manage the National
Suicide Prevention Lifeline. As such, Link2Health Solutions has been
maintaining the network communications system and has an existing
relationship with the networked crisis centers.
The crisis centers that comprise the National Suicide Prevention
Lifeline are a critical part of the nation's mental health safety net.
Many crisis centers are experiencing significant increases in calls.
The National Suicide Prevention Lifeline crisis centers require
assistance to continue to play their critical role in providing support
as well as emergency services to suicidal callers during these
challenging economic times. In addition, the National Suicide
Prevention Lifeline crisis centers are community resources that need to
be utilized to reach out to those in their communities most at risk,
including those currently impacted severely by the economy.
Contact: Shelly Hara, Substance Abuse and Mental Health Services
Administration, 1 Choke Cherry Road, Room 8-1081, Rockville, MD 20857;
telephone: (240) 276-2321; E-mail: shelly.hara@samhsa.hhs.gov.
Toian Vaughn,
Committee Management Officer, Substance Abuse and Mental Health
Services Administration.
[FR Doc. E9-18873 Filed 8-6-09; 8:45 am]
BILLING CODE 4162-20-P
